Magnesium Implant Releases Hydrogen to Fight Prostate Cancer
- Authors
- Rui Zan, Qianping Mao, Keyi Wang, Guodong Zou, Shi Yang, Hua Qiu, Xiang Fang, Guiqing Wang, Xinyi Zhou, Jiexia Wen, Shuai Jiang, Ran Huang, Qiuming Peng, Tao Suo
- Journal
- Advanced Science
- Year
- 2025
- DOI
- 10.1002/advs.202515235
- Study Type
- Cell Culture
- Outcome
- Positive
- Peer Reviewed
- Yes
- Country
- China
- Health Condition
- Prostate Cancer
- Body System
- Reproductive System
TL;DR
A magnesium-based implant released hydrogen at tumor sites, enhancing immune activation and improving prostate cancer treatment effectiveness.
Key Finding
A magnesium-based platform that releases hydrogen gas and delivers therapeutic drugs showed promise in laboratory cell cultures by combining hormone therapy and immune activation to target prostate cancer cells.
Summary
Researchers developed an experimental drug delivery system made from magnesium that releases hydrogen gas and delivers cancer-fighting drugs directly to prostate cancer cells. The system combines hormone therapy (using a compound called ginsenoside Rb1) with immune system activation, and laboratory tests suggest it may trigger cancer cell death and activate immune responses. This is early-stage research conducted in cell cultures, not yet tested in animals or humans.
Practical Takeaway
While this study suggests hydrogen gas release combined with targeted drug delivery may have anti-cancer potential, this is very early laboratory research with no animal or human testing reported. The findings are preliminary and cannot be applied to real-world hydrogen water consumption or cancer treatment at this stage.
Abstract
Metal-based immunotherapy represents a promising strategy for enhancing antitumor efficacy; however, its clinical application is limited by challenges such as inefficient drug delivery, low specificity, and suboptimal therapeutic outcomes. In this study, a therapeutic platform is constructed on a magnesium (Mg) surface utilizing self-healing thiolated hyaluronic acid (HA-SH) and cell membrane-derived vesicle (CMV) drug system, which improves structural stability, enables spatiotemporal drug release, and facilitates immune-hormone combination therapy for prostate cancer. CMV with phospholipid bilayers promotes HA-SH disulfide bond interactions through weak hydrophobic interactions, mitigating corrosion and ensuring structural integrity. Additionally, HA-SH exhibits glutathione (GSH)-responsive drug release within the tumor microenvironment. CMV facilitates pH-sensitive drug delivery and enables efficient cytoplasmic entry via membrane fusion mechanisms, ensuring precise spatiotemporal control. Through drug library screening, ginsenoside Rb1 is identified as a key therapeutic agent, competitively inhibiting androgen receptor signaling. Coupled with hydrogen release from Mg, it induces immunogenic cell death and promotes the formation of tertiary lymphoid structures (TLS) via inhibiting the PI3K-AKT pathway, achieving synergistic androgen deprivation therapy and immune activation. This implantable drug delivery system effectively tackles mechanical stability, local drug delivery, and systemic immune activation concerns, demonstrating substantial translational promise for various malignancies to improve treatment effectiveness and reduce structural failure risks.